misonneh's library 833 articles Export

	5-methylcytosine--the fifth base of DNA: the fifth wheel on a car or a highly promising diagnostic and therapeutic target in cancer? [My Copy] Disease markers, Vol. 23, No. 1-2. (2007), pp. 1-3. by Martin Widschwendter posted to risk_assessment methylation epigenetics comments chemotherapy biomarker 5mdc by misonneh on 2009-11-04 21:48:18 as
	Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. [My Copy] PloS one, Vol. 3, No. 7. (2008) by Martin Widschwendter, Sophia Apostolidou, Elke Raum, et al.Dietrich Rothenbacher, Heidi Fiegl, Usha Menon, Christa Stegmaier, Ian J. Jacobs, Hermann Brenner posted to polycomb peripheral_blood methylation hr gene_specific_methylation epigenetics breast association by misonneh on 2009-11-04 21:44:12 as
	Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. [My Copy] Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 14, No. 11. (1 June 2008), pp. 3494-3502. by Heidi Fiegl, Allison Jones, Cornelia Hauser-Kronberger, et al.Georg Hutarew, Roland Reitsamer, Robin L. Jones, Mitch Dowsett, Elisabeth Mueller-Holzner, Gudrun Windbichler, Günter Daxenbichler, Georg Goebel, Christian Ensinger, Ian Jacobs, Martin Widschwendter posted to response prediction pharmacogenetics neurod1 neoadjuvant methylation gene_specific_methylation epigenetics circ_dna chemotherapy breast by misonneh on 2009-11-04 21:21:37 as
	Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. [My Copy] British journal of cancer, Vol. 101, No. 8. (20 October 2009), pp. 1253-1260. by M. Hauglid Flågeng, Haugan L. Moi, J. M. Dixon, et al.J. Geisler, E. A. Lien, W. R. Miller, P. E. Lønning, G. Mellgren posted to response prediction nuclear_receptor neoadjuvant kim_ her2 expression breast aromatase_inhibitor by misonneh on 2009-11-03 06:03:37 as
	Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. [My Copy] International journal of cancer. Journal international du cancer, Vol. 125, No. 6. (15 September 2009), pp. 1454-1463. by Linda J. Nicholson, Paul R. Smith, Louise Hiller, et al.Peter W. Szlosarek, Christopher Kimberley, Jalid Sehouli, Dominique Koensgen, Alexander Mustea, Peter Schmid, Tim Crook posted to response resistance ovarian methylation dynamic by misonneh on 2009-10-29 08:33:25 as
	Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. [My Copy] Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 15, No. 13. (1 July 2009), pp. 4356-4364. by Masanori Nojima, Reo Maruyama, Hiroshi Yasui, et al.Hiromu Suzuki, Yumiko Maruyama, Isao Tarasawa, Yasushi Sasaki, Hideki Asaoku, Hajime Sakai, Toshiaki Hayashi, Mitsuru Mori, Kohzoh Imai, Takashi Tokino, Tadao Ishida, Minoru Toyota, Yasuhisa Shinomura posted to resistance prognosis multiple_myeloma methylation gwas epigenetic_therapy by misonneh on 2009-10-29 08:29:14 as
	Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. [My Copy] Molecular cancer, Vol. 8 (14 July 2009), 48. by Elizabeth M. Swisher, Rachel M. Gonzalez, Toshiyasu Taniguchi, et al.Rochelle L. Garcia, Tom Walsh, Barbara A. Goff, Piri Welcsh posted to response prognosis ovarian kim_ gene_specific_methylation expression dna_repair chemotherapy by misonneh on 2009-10-29 08:17:46 as
	Targeting DNA methylation. [My Copy] Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 15, No. 12. (15 June 2009), pp. 3938-3946. by Jean-Pierre P. Issa, Hagop M. Kantarjian posted to review methylation epigenetic_therapy drug_discovery by misonneh on 2009-10-29 07:45:57 as
	Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. [My Copy] Human genetics (8 October 2009) by Cristina Rodriguez-Antona, Alvin Gomez, Maria Karlgren, Sarah C. Sim, Magnus Ingelman-Sundberg posted to review response prediction methylation kim_ epidgenetics chemotherapy by misonneh on 2009-10-29 07:13:34 as
	The effect of genetic variability on drug response in conventional breast cancer treatment. [My Copy] European journal of pharmacology (18 October 2009) by Emilia Wiechec, Lise Lotte L. Hansen posted to review response pharmacogenetics metabolism genetics chemotherapy breast by misonneh on 2009-10-29 07:12:29 as
	MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma [My Copy] N Engl J Med, Vol. 352, No. 10. (10 March 2005), pp. 997-1003. by Monika E. Hegi, Annie-Claire Diserens, Thierry Gorlia, et al.Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M. Kros, Johannes A. Hainfellner, Warren Mason, Luigi Mariani, Jacoline E. C. Bromberg, Peter Hau, Rene O. Mirimanoff, J. Gregory Cairncross, Robert C. Janzer, Roger Stupp posted to temozolomide response prognosis prediction mgmt kim_ glioblastoma gene_specific_methylation epigenetics chemotherapy alkylating_agents by misonneh on 2009-10-29 07:06:02 as along with 2 people srp33 alanvelander
	Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 26, No. 25. (1 September 2008), pp. 4189-4199. by Monika E. Hegi, Lili Liu, James G. Herman, et al.Roger Stupp, Wolfgang Wick, Michael Weller, Minesh P. Mehta, Mark R. Gilbert posted to response prognosis prediction mgmt methylation kim_ glioblastoma gene_specific_methylation by misonneh on 2009-10-29 06:53:05 as along with 2 people cornellneurology lrust
	Pharmacokinetics/Genotype Associations for Major Cytochrome P450 Enzymes in Native and First- and Third-generation Japanese Populations: Comparison With Korean, Chinese, and Caucasian Populations [My Copy] Clinical Pharmacology & Therapeutics, Vol. 84, No. 3. (19 March 2008), pp. 347-361. by S. P. Myrand, K. Sekiguchi, M. Z. Man, et al.X. Lin, R. Y. Tzeng, C. H. Teng, B. Hee, M. Garrett, H. Kikkawa, C. Y. Lin, S. M. Eddy, J. Dostalik, J. Mount, J. Azuma, Y. Fujio, I. J. Jang, S. G. Shin, M. R. Bleavins, J. A. Williams, J. D. Paulauskis, K. D. Wilner posted to race pk phenotype genotype cyp450 by misonneh on 2009-10-28 23:47:50 as along with 2 people and 1 group kjkj0001 parkjs80 Asian Pharmacogenetics Library
	Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. [My Copy] Cancer, Vol. 115, No. 5. (1 March 2009), pp. 952-961. by Masatsugu Okishiro, Tetsuya Taguchi, Seung Jin Kim, Kenzo Shimazu, Yasuhiro Tamaki, Shinzaburo Noguchi posted to tamoxifen pharmacogenetics cyp2d6 breast asian_populations by misonneh on 2009-10-27 07:17:16 as along with 2 people ilsun Mi-Seon
	Impact of CYP2D610 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. [My Copy] Cancer science*, Vol. 99, No. 5. (May 2008), pp. 995-999. by Kazuma Kiyotani, Taisei Mushiroda, Mitsunori Sasa, et al.Yoshimi Bando, Ikuko Sumitomo, Naoya Hosono, Michiaki Kubo, Yusuke Nakamura, Hitoshi Zembutsu posted to pharmacogenetics cyp2d6 breast asian_populations by misonneh on 2009-10-27 07:12:50 as
	Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. [My Copy] Journal of the National Cancer Institute, Vol. 95, No. 23. (3 December 2003), pp. 1758-1764. by Vered Stearns, Michael D. Johnson, James M. Rae, et al.Alan Morocho, Antonella Novielli, Pankaj Bhargava, Daniel F. Hayes, Zeruesenay Desta, David A. Flockhart posted to tamoxifen pk pharmacogenetics metabolism ddi breast by misonneh on 2009-10-27 07:02:30 as
	CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. [My Copy] Journal of the National Cancer Institute, Vol. 97, No. 1. (5 January 2005), pp. 30-39. by Yan Jin, Zeruesenay Desta, Vered Stearns, et al.Bryan Ward, Herbert Ho, Kyung-Hoon H. Lee, Todd Skaar, Anna Maria M. Storniolo, Lang Li, Adjei Araba, Rebecca Blanchard, Anne Nguyen, Lynda Ullmer, Jill Hayden, Suzanne Lemler, Richard M. Weinshilboum, James M. Rae, Daniel F. Hayes, David A. Flockhart posted to tamoxifen pharmacogenetics genetics ddi cyp2d6 breast by misonneh on 2009-10-27 07:01:49 as along with 1 person frohike
	Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. [My Copy] Clinical pharmacology and therapeutics, Vol. 80, No. 1. (July 2006), pp. 61-74. by Silvana Borges, Zeruesenay Desta, Lang Li, et al.Todd C. Skaar, Bryan A. Ward, Anne Nguyen, Yan Jin, Anna Maria M. Storniolo, D. Michele Nikoloff, Lin Wu, Grant Hillman, Daniel F. Hayes, Vered Stearns, David A. Flockhart posted to tamoxifen pk pharmacogenetics metabolism cyp2d6 breast by misonneh on 2009-10-27 07:01:06 as
	Germline pharmacogenetics of tamoxifen response: have we learned enough? [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 25, No. 33. (20 November 2007), pp. 5147-5149. by Zeruesenay Desta, David A. Flockhart posted to tamoxifen pharmacogenetics genetics cyp2d6 comments breast by misonneh on 2009-10-27 06:59:30 as
	Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. [My Copy] JAMA : the journal of the American Medical Association, Vol. 302, No. 13. (7 October 2009), pp. 1429-1436. by Werner Schroth, Matthew P. Goetz, Ute Hamann, et al.Peter A. Fasching, Marcus Schmidt, Stefan Winter, Peter Fritz, Wolfgang Simon, Vera J. Suman, Matthew M. Ames, Stephanie L. Safgren, Mary J. Kuffel, Hans Ulrich U. Ulmer, Julia Boländer, Reiner Strick, Matthias W. Beckmann, Heinz Koelbl, Richard M. Weinshilboum, James N. Ingle, Michel Eichelbaum, Matthias Schwab, Hiltrud Brauch posted to tamoxifen prognosis prediction pharmacogenetics genotype cyp2d6 breast by misonneh on 2009-10-26 06:36:40 as along with 1 person merpublic
	Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. [My Copy] Breast cancer research and treatment, Vol. 115, No. 3. (June 2009), pp. 643-650. by Adedayo A. Onitilo, Catherine A. McCarty, Russell A. Wilke, et al.Ingrid Glurich, Jessica M. Engel, David A. Flockhart, Anne Nguyen, Lang Li, Deming Mi, Todd C. Skaar, Yan Jin posted to tamoxifen pharmacogenetics hr genetics breast adr by misonneh on 2009-10-21 02:21:36 as
	Multiparity and the risk of premenopausal breast cancer: different effects across ethnic groups in Singapore. [My Copy] Breast cancer research and treatment, Vol. 113, No. 3. (February 2009), pp. 553-558. by Helena M. Verkooijen, Karen P. Yap, Vineta Bhalla, Khuan Yew Y. Chow, Kee Seng S. Chia posted to risk_factor race parity hormone estrogen epidemiology breast by misonneh on 2009-10-21 01:30:03 as
	Do Asian breast cancer patients have poorer survival than their western counterparts? A comparison between Singapore and Stockholm. [My Copy] Breast cancer research : BCR, Vol. 11, No. 1. (24 January 2009), R4. by Benita Kiat Tee K. Tan, Gek Hsiang H. Lim, Kamila Czene, Per Hall, Kee Seng S. Chia posted to trend survival prognosis epidemiology breast asian_populations by misonneh on 2009-10-21 01:27:20 as
	Singapore Genome Variation Project: A haplotype map of three Southeast Asian populations. [My Copy] Genome research, Vol. 19, No. 11. (29 September 2009), pp. 2154-2162. by Yik-Ying Y. Teo, Xueling Sim, Rick T. Ong, et al.Adrian K. Tan, Jieming Chen, Erwin Tantoso, Kerrin S. Small, Chee-Seng S. Ku, Edmund J. Lee, Mark Seielstad, Kee-Seng S. Chia posted to statistics read_ haplotype genetics database asian_populations by misonneh on 2009-10-21 01:26:00 as along with 4 people jasontsai daforerog djkt pkonings
	CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. [My Copy] Breast cancer research : BCR, Vol. 9, No. 6. (17 December 2007), R87. by Francisco J. Esteva, Jing Wang, Feng Lin, et al.Jaime A. Mejia, Kai Yan, Kadri Altundag, Vicente Valero, Aman U. Buzdar, Gabriel N. Hortobagyi, W. Fraser Symmans, Lajos Pusztai posted to response prediction neoadjuvant immunity her2 breast biomarker by misonneh on 2009-10-19 08:49:42 as
	Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. [My Copy] Journal of the National Cancer Institute, Vol. 100, No. 3. (6 February 2008), pp. 207-212. by Giuseppe Viale, Meredith M. Regan, Mauro G. Mastropasqua, et al.Fausto Maffini, Eugenio Maiorano, Marco Colleoni, Karen N. Price, Rastko Golouh, Tiziana Perin, R. W. Brown, Anikó Kovács, Komala Pillay, Christian Ohlschlegel, Barry A. Gusterson, Monica Castiglione-Gertsch, Richard D. Gelber, Aron Goldhirsch, Alan S. Coates, International Breast Cancer Study Group posted to prognosis prediction ki67 hormone chemotherapy breast biomarker by misonneh on 2009-10-19 08:47:32 as
	Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 26, No. 8. (10 March 2008), pp. 1275-1281. by Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess, et al.Fabrice André, Attila Tordai, Jaime A. Mejia, W. Fraser Symmans, Ana M. Gonzalez-Angulo, Bryan Hennessy, Marjorie Green, Massimo Cristofanilli, Gabriel N. Hortobagyi, Lajos Pusztai posted to survival prognosis prediction neoadjuvant chemotherapy breast biomarker by misonneh on 2009-10-19 08:44:43 as
	Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. [My Copy] Breast cancer research and treatment, Vol. 112, No. 3. (9 December 2008), pp. 475-488. by Djuana M. Harvell, Nicole S. Spoelstra, Meenakshi Singh, et al.James L. McManaman, Christina Finlayson, Tzu Phang, Susan Trapp, Lawrence Hunter, Wendy W. Dye, Virginia F. Borges, Anthony Elias, Kathryn B. Horwitz, Jennifer K. Richer posted to resonse resistance neoadjuvant hormone chemotherapy breast biomarker by misonneh on 2009-10-19 08:44:01 as along with 1 person jfr
	Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. [My Copy] Breast cancer research : BCR, Vol. 10, No. 2. (01 April 2008), R30. by Gunter von Minckwitz, Hans-Peter P. Sinn, Günter Raab, et al.Sibylle Loibl, Jens-Uwe U. Blohmer, Holger Eidtmann, Jörn Hilfrich, Elisabeth Merkle, Christian Jackisch, Serban D. Costa, Angelika Caputo, Manfred Kaufmann, German Breast Group posted to response neoadjuvant dynamic chemotherapy breast biomarker by misonneh on 2009-10-19 08:42:21 as
	The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. [My Copy] Breast cancer research and treatment, Vol. 116, No. 1. (1 July 2009), pp. 53-68. by Robin L. Jones, Janine Salter, Roger A'Hern, et al.Ash Nerurkar, Marina Parton, Jorge S. Reis-Filho, Ian E. Smith, Mitchell Dowsett posted to prediction neoadjuvant dynamic chemotherapy breast biomarker by misonneh on 2009-10-19 08:39:43 as along with 1 person Zephyrus
	Changes in tumour biological markers during primary systemic chemotherapy (PST). [My Copy] Anticancer research, Vol. 28, No. 3B. (n 2008), pp. 1797-1804. by Hans Neubauer, Christian Gall, Ulrich Vogel, et al.Rene Hornung, Diethelm Wallwiener, Erich Solomayer, Tanja Fehm posted to response dynamic chemotherapy breast biomarker by misonneh on 2009-10-19 08:37:21 as
	Predicting response to neoadjuvant chemotherapy in breast cancer: molecular imaging, systemic biomarkers and the cancer metabolome (Review). [My Copy] Oncology reports, Vol. 20, No. 4. (October 2008), pp. 699-703. by Suebwong Chuthapisith, Jennifer M. Eremin, Oleg Eremin posted to review response neoadjuvant chemotherapy biomarker by misonneh on 2009-10-19 08:34:52 as
	Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. [My Copy] Cancer investigation, Vol. 26, No. 10. (December 2008), pp. 1024-1031. by Helena Hornychova, Bohuslav Melichar, Marketa Tomsova, Jindøiska Mergancova, Hana Urminska, Ales Ryska posted to response neoadjuvant immunity chemotherapy breast biomarker by misonneh on 2009-10-19 08:17:43 as
	Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 26, No. 5. (10 February 2008), pp. 814-819. by Julie R. Gralow, Harold J. Burstein, William Wood, et al.Gabriel N. Hortobagyi, Luca Gianni, Gunter von Minckwitz, Aman U. Buzdar, Ian E. Smith, William F. Symmans, Baljit Singh, Eric P. Winer posted to review response prognosis prediction neoadjuvant breast by misonneh on 2009-10-19 08:15:04 as
	Stromal matrix protein expression following preoperative systemic therapy in breast cancer. [My Copy] Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 15, No. 2. (15 January 2009), pp. 731-739. by Anna-Maria M. Tokes, Attila Marcell M. Szasz, Andrea Farkas, et al.Adrienn Ildiko I. Toth, Magdolna Dank, Laszlo Harsanyi, Bela Akos A. Molnar, Istvan Arthur A. Molnar, Zsolt Laszlo, Zoltan Rusz, Janina Kulka posted to stromal_component response neoadjuvant expression chemotherapy breast by misonneh on 2009-10-19 08:13:43 as
	Supervised risk predictor of breast cancer based on intrinsic subtypes. [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 27, No. 8. (10 March 2009), pp. 1160-1167. by Joel S. Parker, Michael Mullins, Maggie C. Cheang, et al.Samuel Leung, David Voduc, Tammi Vickery, Sherri Davies, Christiane Fauron, Xiaping He, Zhiyuan Hu, John F. Quackenbush, Inge J. Stijleman, Juan Palazzo, J. S. Marron, Andrew B. Nobel, Elaine Mardis, Torsten O. Nielsen, Matthew J. Ellis, Charles M. Perou, Philip S. Bernard posted to time_to_event subtypes risk_assessment response prognosis prediction genetics breast by misonneh on 2009-10-19 08:08:31 as along with 2 people ptrobajo jfr
	Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma? [My Copy] The breast journal, Vol. 15, No. 2. (r 2009), pp. 146-154. by Peggy S. Sullivan, Sophia K. Apple posted to response neoadjuvant histology chemotherapy breast by misonneh on 2009-10-19 08:04:25 as
	Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. [My Copy] Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 15, No. 12. (15 June 2009), pp. 4234-4241. by Tomonori Tanei, Koji Morimoto, Kenzo Shimazu, et al.Seung Jin J. Kim, Yoshio Tanji, Tetsuya Taguchi, Yasuhiro Tamaki, Shinzaburo Noguchi posted to response resistance neoadjuvant kim_ expression chemotherapy breast aldh1 by misonneh on 2009-10-19 07:55:29 as
	Joint effects of genetic hitchhiking and background selection on neutral variation. [My Copy] Genetics, Vol. 155, No. 3. (July 2000), pp. 1415-1427. by Y. Kim, W. Stephan posted to linkage hitchhiking haplotype genetics by misonneh on 2009-10-14 07:34:24 as
	The hitchhiking effect on linkage disequilibrium between linked neutral loci. [My Copy] Genetics, Vol. 172, No. 4. (1 April 2006), pp. 2647-2663. by Wolfgang Stephan, Yun S. Song, Charles H. Langley posted to linkage hitchhiking haplotype genetics by misonneh on 2009-10-14 07:05:03 as along with 4 people and 1 group renewang ccots balicea dmc Durbin group
	The "hitchhiking effect" revisited. [My Copy] Genetics, Vol. 123, No. 4. (1 December 1989), pp. 887-899. by N. L. Kaplan, R. R. Hudson, C. H. Langley posted to statistics moa linkage hitchhiking haplotype genetics by misonneh on 2009-10-14 07:04:25 as along with 2 people renewang djkt
	Development of the 21-gene assay and its application in clinical practice and clinical trials. [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 26, No. 5. (10 February 2008), pp. 721-728. by Joseph A. Sparano, Soonmyung Paik posted to review randomized_controlled_trial pharmacogenetics oncotypedx genetics design clinic biomarker by misonneh on 2009-10-13 01:05:56 as along with 1 person frohike
	The impact of FDA guidance on pharmacogenomic data submissions on drug development. [My Copy] IDrugs : the investigational drugs journal, Vol. 8, No. 8. (August 2005), pp. 648-650. by Stephen Little posted to pharmacogenetics guideline fda drug_discovery by misonneh on 2009-10-12 22:36:59 as
	Pharmacogenetics in drug discovery and development: a translational perspective. [My Copy] Nature reviews. Drug discovery, Vol. 7, No. 10. (19 October 2008), pp. 807-817. by Allen D. Roses posted to translation review pharmacogenetics drug_discovery by misonneh on 2009-10-12 22:09:29 as along with 5 people guhjy nicklynch pengchy sg45653 dunnma
	Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels [My Copy] (February 2009) posted to summary pharmacogenetics fda biomarker by misonneh on 2009-10-11 02:14:54 as
	E15 Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories [My Copy] (April 2008) posted to pharmacogenetics guideline fda by misonneh on 2009-10-11 01:37:40 as
	Guidance on Pharmacogenetic Tests and Genetic Tests for Heritable Markers [My Copy] (19 June 2007) by Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research posted to pharmacogenetics guideline fda by misonneh on 2009-10-11 01:18:53 as
	Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. [My Copy] The oncologist, Vol. 13, No. 12. (December 2008), pp. 1235-1245. by Frédérique Penault-Llorca, Catherine Abrial, Inès Raoelfils, et al.Philippe Chollet, Anne Cayre, Marie-Ange A. Mouret-Reynier, Emilie Thivat, Florence Mishellany, Pierre Gimbergues, Xavier Durando posted to response neoadjuvant expression chemotherapy breast biomarker by misonneh on 2009-10-09 08:42:24 as
	Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. [My Copy] Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 27, No. 16. (1 June 2009), pp. 2630-2637. by José Baselga, Vladimir Semiglazov, Peter van Dam, et al.Alexey Manikhas, Meritxell Bellet, José Mayordomo, Mario Campone, Ernst Kubista, Richard Greil, Giulia Bianchi, Jutta Steinseifer, Betty Molloy, Erika Tokaji, Humphrey Gardner, Penny Phillips, Michael Stumm, Heidi A. Lane, J. Michael Dixon, Walter Jonat, Hope S. Rugo posted to response neoadjuvant expression chemotherapy breast by misonneh on 2009-10-09 08:10:36 as
	Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. [My Copy] British journal of cancer, Vol. 92, No. 1. (17 January 2005), pp. 147-155. by R. J. Burcombe, A. Makris, P. I. Richman, et al.F. M. Daley, S. Noble, M. Pittam, D. Wright, S. A. Allen, J. Dove, G. D. Wilson posted to response neoadjuvant expression chemotherapy breast by misonneh on 2009-10-09 08:08:16 as

Note: You may cite this page as: http://www.citeulike.org/user/misonneh

Result page: 1 2 3 4 5 6 7 8 9 10 Next

review	275
breast	234
epigenetics	153
genetics	150
methylation	146
pharmacogenetics	113
statistics	84
gene_specific_methylation	62
gwas	60
prognosis	58
comments	57
biomarker	56
tamoxifen	51
association	48
peripheral	47
gxe	46
chemotherapy	44
diet	42
moa	40
folate	38
modeling	38
guideline	35
resistance	35
global	33
meta_analysis	32
prediction	32
response	31
epistasis	30
adr	28
korean	28
survival	28
epidemiology	27
diagnosis	26
prostate	26
haplotype	25
technology	25
dynamic	23
expression	23
time_to_event	23
circ_dna	21
colon	21
cyp2d6	21
instability	21
neoadjuvant	20
environment	19
prevention	19
race	19
lung	17
progression	17
line1	16
pooling	16
therapy	16
immunity	14
perspective	14
risk_factor	14
clinic	13
invivo	13
target_dna	13
tool	13
5mdc	12
age	12
hr	12
randomized_controlled_trial	12
tutorial	12
1-carbon	11
gxg	11
hematology	11
bladder	10
phenotype	10
data_mining	9
exposure	9
gst	9
hormone	9
metastasis	9
pk	9
smoking	9
bias	8
database	8
esr1	8
estrogen	8
fda	8
ivive	8
cnv	7
dnmt	7
etiology	7
heterogeneity	7
hla	7
lifestyle	7
mirna	7
mthfr	7
power	7
reproductive	7
trend	7
alcohol	6
cancer	6
carbamazepine	6
cell	6
cohort	6
cyp450	6
ddi	6
dna_repair	6
drug_discovery	6
epilepsy	6
her2	6
histone	6
hyper_hypo	6
kim_	6
maternal	6
metabolism	6
pathway	6
pcb	6
prenatal	6
summary	6
system_biology	6
benign	5
cervix	5
chemoprevention	5
fundamental_concept_s1	5
inheritance	5
intervention	5
mdr1	5
mgmt	5
mhc	5
microarray	5
nos3	5
asian_populations	4
balanced	4
bmd	4
cimp	4
cns	4
design	4
leukemia	4
linkage	4
methodology	4
mortality	4
ntissue	4
observation	4
refractory	4
subtypes	4
translation	4
tsnp	4
aml	3
antioxidant	3
array	3
cyp1a1	3
cytokine	3
demethylation	3
detection	3
fu	3
glioblastoma	3
hitchhiking	3
mds	3
molecular	3
pathology	3
pet	3
public	3
ros	3
sult1a1	3
sult1e1	3
swog	3
toxicity	3
validation	3
allergy	2
aromatase_inhibitor	2
aspirin	2
atm	2
bayesian	2
benzopyrene	2
biobank	2
bisphenol	2
brain	2
brca	2
brca12	2
caret	2
childhood	2
classification	2
consorcium	2
cyp2c19	2
cyp2e1	2
decitabine	2
definition	2
diabetes	2
egfr_pathway	2
endometrix	2
epigenetic_therapy	2
finasteride	2
fprp	2
genotype	2
hematopoiety	2
immortalization	2
insilico	2
irinotecan	2
iron	2
isoflavone	2
kawasaki	2
lymphoma	2
metformin	2
mnsod	2
nqo1	2
nutrition	2
oral	2
ovarian	2
ovary	2
parent_study	2
phase	2
radiotherapy	2
risk_assessment	2
s8897	2
slco1b1	2
specimen	2
statin	2
testicular	2
toxicology	2
ugt	2
wnt	2
abacavir	1
acs	1
aldh1	1
aldh2	1
alkylating_agents	1
alternative	1
anthracycline	1
antidepressant	1
apoptosis	1
assay	1
azacitidine	1
benzene	1
bmp	1
casp8	1
cat	1
catechol	1
cbr3	1
cdk	1
cell_cycle_control	1
cluster	1
cml	1
compliance	1
comt	1
confounder	1
consortium	1
cyclophosphamide	1
cyp19	1
cyp1a2	1
cyp1b1	1
cyp2c9	1
cyp3a4	1
dag	1
dcic	1
decision	1
ecadherin	1
endpoint	1
epidgenetics	1
example	1
family_hx	1
fastsnp	1
fmr1	1
fun	1
glioma	1
gpx1	1
heritability	1
hif1a	1
histology	1
history	1
hnscc	1
ho1	1
hogg1	1
hpv	1
illumina	1
immunoprecipitation	1
infection	1
inflammtion	1
integration	1
interleukin	1
intrauterine	1
invitro	1
ki67	1
lactation	1
lipidadjust	1
liver	1
maspin	1
mbd2	1
metabolomics	1
meternal	1
methotrexate	1
mining	1
mpo	1
mrp3	1
multiple_myeloma	1
multitest	1
myc	1
networking	1
neurod1	1
nhs	1
no	1
nrf2	1
nsaid	1
nuclear_receptor	1
obesity	1
oncotypedx	1
opg	1
oralscc	1
osteoporosis	1
outcome	1
parity	1
paternal	1
pax2	1
peakbmd	1
peripheral_blood	1
pharmacodynamic	1
pharmacogenomics	1
pharmacokinetic_variability	1
phytoestrogen	1
plink	1
polycomb	1
polymapr	1
polyphenol	1
practice	1
prevalence	1
proression	1
protocol	1
psychoses	1
qsar	1
quantitative_traits	1
rank	1
rcc	1
read_	1
resonse	1
rfc	1
s100p	1
sat2	1
scn	1
series	1
sfrp5	1
silencing_rna	1
splicing	1
sputum	1
src	1
steroid	1
stromal_component	1
tea	1
temozolomide	1
tgf	1
tgm2	1
tp53	1
tpmt	1
transport	1
ugt1a1	1
warfarin	1
xpd	1
xrcc1	1
xrcc3	1

misonneh's library 833 articles Export

misonneh's tags